MedTrace Logo

Evaluation of Dosing Interval of Higher Doses of Ranibizumab

NCT00533520 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2013-11-25

No results posted yet for this study

Summary

Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).

Conditions

  • Macular Degeneration
  • Choroidal Neovascularization

Interventions

DRUG

ranibizumab

Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Brandon G. Busbee, MD

    lead OTHER

Principal Investigators

  • Brandon G Busbee, MD · Tennessee Retina, P.C,.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00533520 on ClinicalTrials.gov